title: Hepatitis C genotype 3 disease.
abstract: Hepatitis C genotype 3 (GT-3) infection comprises up to 30 % of all HCV infections worldwide, with roughly 54.3 million cases concentrated in South and Southeast Asia. Longitudinal studies have demonstrated significantly increased rates of steatosis, fibrosis, and hepatocellular carcinoma in GT-3 disease, thus distinguishing this genotype as both the most difficult and urgent to treat. However, novel direct-acting antiviral agents currently approved have not demonstrated the uniform potency seen in GT-1 disease for GT-3. This review outlines (1) the epidemiology and natural history, (2) phase II and III clinical trials demonstrating effective treatment options, and (3) current and future therapeutic issues in the quest to eradicate hepatitis C genotype 3 disease.
authors.affiliation: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA. skattakuzhy@ihv.umaryland.edu.
authors.forename: Sarah
authors.initials: S
authors.lastname: Kattakuzhy
authors.affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Levy
authors.affiliation: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA.
authors.forename: Elana
authors.initials: E
authors.lastname: Rosenthal
authors.affiliation: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA.
authors.forename: Lydia
authors.initials: L
authors.lastname: Tang
authors.affiliation: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA.
authors.forename: Eleanor
authors.initials: E
authors.lastname: Wilson
authors.affiliation: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA.
authors.forename: Shyam
authors.initials: S
authors.lastname: Kottilil
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000821:virology; D002986:Clinical Trials as Topic; D005234:Fatty Liver / Q000453:epidemiology / Q000821:virology; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000821:virology; D008113:Liver Neoplasms / Q000453:epidemiology / Q000821:virology; D008137:Longitudinal Studies
chemical_list: D000998:Antiviral Agents
keywords: Genotype-3; Hepatitis C; Treatment review